Associations between plasma nesfatin-1 levels and the presence and severity of coronary artery disease
- 44 Downloads
Nesfatin-1 is a recently identified anorexigenic peptide mainly secreted from the brain and adipose tissue. Although nesfatin-1 may have pro-inflammatory and apoptotic properties, the association between plasma nesfatin-1 levels and coronary artery disease (CAD) has not been clarified yet. We investigated plasma nesfatin-1 levels in 302 patients undergoing elective coronary angiography. Of the 302 study patients, CAD was present in 172 (57%), of whom 67 had 1-vessel, 49 had 2-vessel, and 56 had 3-vessel disease. Compared with 130 patients without CAD, 172 with CAD had higher plasma nesfatin-1 levels (median 0.21 vs. 0.17 ng/mL, P < 0.01). A stepwise increase in nesfatin-1 levels was found depending on the number of > 50% stenotic coronary vessels: 0.17 in CAD(−), 0.20 in 1-vessel, 0.21 in 2-vessel, and 0.22 ng/mL in 3-vessel disease (P < 0.05). A high nesfatin-1 level (> 0.19 ng/mL) was found in 43% of patients with CAD(−), 55% of those with 1-vessel, 55% of those with 2-vessel, and 68% of those with 3-vessel disease (P < 0.05). Nesfatin-1 levels significantly correlated with the number of > 50% stenotic coronary segments (r = 0.14, P < 0.02). In multivariate analysis, plasma nesfatin-1 levels were a significant factor for CAD independent of atherosclerotic risk factors. The odds ratio for CAD was 1.71 (95% CI 1.01–2.91) for high nesfatin-1 level of > 0.19 ng/mL (P < 0.05). Thus, plasma nesfatin-1 levels were found to be high in patients with CAD and were associated with CAD independent of atherosclerotic risk factors, suggesting that high nesfatin-1 levels in patients with CAD may play a role in the development of coronary atherosclerosis.
KeywordsAtherosclerosis Biomarker Coronary artery disease Nesfatin-1
This study was supported in part by a grant from Honjo International Scholarship Foundation. Financial funding was also provided in part by Bayer Yakuhin Ltd. and Pfizer Japan Inc.; however, these sponsors had no role in the design, analysis, or interpretation of our study.
Compliance with ethical standards
Conflict of interest
Our study has no conflicts of interest to disclose.
- 2.Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, Kern W, Hillhouse EW, Lehnert H, Tan BK, Randeva HS (2010) Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 151(7):3169–3180CrossRefGoogle Scholar
- 6.Algul S, Ozkan Y, Ozcelik O (2016) Serum nesfatin-1 levels in patients with different glucose tolerance levels. Physiol Res 65(6):979–985Google Scholar
- 12.Jiang L, Bao J, Zhou X, Xiong Y, Wu L (2013) Increased serum levels and chondrocyte expression of nesfatin-1 in patients with osteoarthritis and its relation with BMI, hsCRP, and IL-18. Mediat Inflamm 2013:631251Google Scholar
- 16.Sahin FK, Sahin SB, Ural UM, Cure MC, Senturk S, Tekin YB, Balik G, Cure E, Yuce S, Kirbas A (2015) Nesfatin-1 and vitamin D levels may be associated with systolic and diastolic blood pressure value and hearth rate in polycystic ovary syndrome. Bosn J Basic Med Sci 15(3):57–63Google Scholar
- 18.Lu QB, Wand HP, Tang ZH, Cheng H, Du Q, Wang YB, Feng WB, Li KX, Cai WW, Qiu LY, Sun HJ (2018) Nesfatin-1 functions as a switch for phenotype transformation and proliferation of VSMCs in hypertensive vascular remodeling. Biochim Biophys Acta 1864 1864(6 Pt A):2154–2168Google Scholar
- 23.Tsuchiya T, Shimizu H, Yamada M, Osaki A, Oh-I S, Ariyama Y, Takahashi H, Okada S, Hashimoto K, Satoh T, Kojima M, Mori M (2010) Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males. Clin Endocrinol 73(4):484–490Google Scholar